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Background:  Production of trimethylamine-N-oxide (TMAO) by gut-microbiota metabolite from dietary phosphatidylcholine has been 
associated with the development of atherosclerosis in animals and in humans. The ability of plasma TMAO to predict future risk of major 
adverse cardiac events (MACE=death, myocardial infarction, and stroke) in patients with peripheral artery disease (PAD) have not been 
described.
methods:  We examined the relationship between fasting plasma TMAO and incident MACE over 3-year follow-up in 935 patients with a 
history of PAD undergoing elective coronary angiography.
results:  In our study cohort (mean age = 66.0±11 years, 65% men), median TMAO was 4.7 (2.8-7.8). Elevated plasma TMAO levels was 
associated with 2-fold increased risk of future MACE (Quartiles 4th vs 1st: Hazard ratio [HR] 1.96, 95%CI 1.38-2.79, p<0.001; Figure) as 
well as myocardial infarction/stroke alone (HR 1.97, 95%CI 1.38-2.79, p<0.001). Following adjustments for traditional risk factor, the highest 
TMAO quartile remained predictive of 3-year MACE risk (adjusted HR 1.74, 95%CI 1.2 - 2.51], p <0.001). Addition of TMAO to traditional 
risk factors reclassifies risk of MACE in 15.9% of subjects (IDI 5.9%, p<0.001; NRI 15.9%, p<0.001, AUC 0.6 to 0.64, p=0.019).
conclusion:  Elevated plasma TMAO levels, a pro-atherogenic metabolite formed by gut microbiota metabolism of the choline group of 
phosphatidylcholine, portend stronger incident risk of MACE in patients with PAD, independent of traditional risk factors.
 
